A Form 144 notice of proposed sale was filed on November 19, 2026, by the Kumar Haldea Family Irrevocable Trust, disclosing plans to sell 30,000 shares of BridgeBio Pharma Inc. common stock on NASDAQ.
Key Highlights
- Proposed sale: The Kumar Haldea Family Irrevocable Trust intends to sell 30,000 shares of BridgeBio Pharma Inc. common stock with an aggregate market value of $2,340,300.00.
- Approximate sale date: The filing lists November 19, 2026 as the approximate date of sale, through Morgan Stanley Smith Barney LLC Executive Financial Services.
- Original acquisition: The 30,000 shares were acquired on March 26, 2016, via conversion of management incentive units from the issuer.
- 10b5-1 plan: The filing indicates the sale relies on a Rule 10b5-1 plan adopted on May 13, 2026.
- Shares outstanding: According to the filing, 194,800,782 shares of BridgeBio Pharma common stock were outstanding at the time of the notice.
- Recent prior sales: The trust sold 10,000 shares on November 18, 2026, for gross proceeds of $777,199.00, and 10,000 shares on September 17, 2026, for gross proceeds of $690,847.00, both under 10b5-1 plans.
- Relationship to issuer: The filing identifies the account holder's relationship to the issuer as both Director and Officer.
Kumar Haldea Family Irrevocable Trust Proposes BridgeBio Share Sale Under 10b5-1 Plan
The Form 144 notice, filed with the SEC on November 19, 2026, discloses that the Kumar Haldea Family Irrevocable Trust proposes to sell 30,000 shares of BridgeBio Pharma Inc. (NASDAQ:BBIO) common stock, with an aggregate market value of $2,340,300.00. The broker named in the filing is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The filing was signed by Neil Kumar.
According to the filing, the shares proposed for sale were originally acquired on March 26, 2016, through the conversion of management incentive units from the issuer, with payment recorded as "N/A." The notice states that the sale is being made pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026. BridgeBio Pharma is located at 3160 Porter Drive, Suite 250, Palo Alto, California 94304, and its SEC file number is listed as 001-38959.
The filing also discloses sales made in the prior three months. The Kumar Haldea Family Irrevocable Trust sold 10,000 shares on November 18, 2026, for gross proceeds of $777,199.00, and an additional 10,000 shares on September 17, 2026, for gross proceeds of $690,847.00, both under 10b5-1 plans. Separately, the filing lists sales attributed to Neil Kumar personally: 34,980 shares sold on November 18, 2026, for gross proceeds of $2,718,642.10 under a 10b5-1 plan, and 36,236 shares sold on November 16, 2026, for gross proceeds of $2,803,216.96.
What Was Disclosed
The filing is a Form 144 notice of proposed sale, submitted on November 19, 2026, by the Kumar Haldea Family Irrevocable Trust, covering a planned sale of 30,000 BridgeBio Pharma Inc. common shares valued at $2,340,300.00, under a 10b5-1 plan adopted May 13, 2026.



Please wait processing your request...